Skip to main content

Market Overview

Benzinga's Top Upgrades, Downgrades For October 16, 2018

Share:

Top Upgrades

  • BMO Capital upgraded Marvell Technology Group Ltd. (NASDAQ: MRVL) from Market Perform to Outperform. Marvell Technology shares rose 1.55 percent to $18.40 in pre-market trading.
  • HSBC upgraded Las Vegas Sands Corp. (NYSE: LVS) from Hold to Buy. Las Vegas Sands shares rose 0.5 percent to $56.10 in pre-market trading.
  • Morgan Stanley upgraded Government Properties Income Trust (NASDAQ: GOV) from Underweight to Equal-Weight. Government Properties Income Trust shares rose 1.8 percent to $10.00 in pre-market trading.
  • B. Riley upgraded Arbutus Biopharma Corp (NASDAQ: ABUS) from Neutral to Buy. Arbutus Biopharma shares fell 3.94 percent to close at $4.14 on Monday.

 

Top Downgrades

  • KeyBanc downgraded Integrated Device Technology Inc (NASDAQ: IDTI) from Overweight to Sector Weight. Integrated Device Tech shares fell 0.41 percent to $46.57 in pre-market trading.
  • Jefferies downgraded Pinnacle Foods Inc (NYSE: PF) from Buy to Hold. Pinnacle Foods shares dropped 0.42 percent to $65.85 in pre-market trading.
  • Stifel Nicolaus downgraded Antero Midstream Partners LP (NYSE: AM) from Buy to Hold. Antero Midstream Partners shares fell 0.21 percent to $32.65 in pre-market trading.
  • Bank of America downgraded Spero Therapeutics Inc (NASDAQ: SPRO) from Neutral to Underperform. Spero Therapeutics shares rose 1.67 percent to close at $9.76 on Monday.
  • SunTrust Robinson Humphrey downgraded Amneal Pharmaceuticals Inc (NYSE: AMRX) from Buy to Hold. Amneal Pharmaceuticals shares fell 1.8 percent to $18.40 in pre-market trading.

 

Top Initiations

  • Barclays initiated coverage on Stryker Corporation (NYSE: SYK) with an Overweight rating. The price target for Stryker is set to $198. Stryker shares closed at $169.41 on Monday.
  • Benchmark initiated coverage on Tilray Inc (NASDAQ: TLRY) with a Buy rating. The price target for Tilray is set to $200. Tilray shares closed at $165.64 on Monday.
  • Analysts at Bank Of America initiated coverage on Y-mAbs Therapeutics, Inc (NASDAQ: CAMP) with a Buy rating. The price target for Y-mAbs Therapeutics is set to $26. Y-mAbs Therapeutics shares closed at $21.60 on Monday.
  • Analysts at Bernstein initiated coverage on Philip Morris International Inc. (NYSE: PM) with an Outperform rating. The price target for Philip Morris is set to $97. Philip Morris shares closed at $83.49 on Monday.
  • Barclays initiated coverage on Abbott Laboratories (NYSE: ABT) with an Overweight rating. The price target for Abbott is set to $80. Abbott shares closed at $68.70 on Monday.
  • Analysts at Bernstein initiated coverage on Altria Group Inc (NYSE: MO) with a Market Perform rating. Altria closed at $61.44 on Monday.
  • Citigroup initiated coverage on Independence Realty Trust Inc (NYSE: IRT) with a Neutral rating. Independence Realty Trust shares closed at $9.78 on Monday.
  • BTIG Research initiated coverage on Esperion Therapeutics Inc (NASDAQ: ESPR) with a Buy rating. The price target for Esperion Therapeutics is set to $82. Esperion Therapeutics shares closed at $44.94 on Monday.
  • Barclays initiated coverage on Becton Dickinson and Co (NYSE: BDX) with an Equal-Weight rating. The price target for Becton Dickinson is set to $278. Becton Dickinson shares closed at $238.31 on Monday.
 

Related Articles (ABT + ABUS)

View Comments and Join the Discussion!

Posted-In: Initiations top upgradesUpgrades Downgrades Initiation Pre-Market Outlook Analyst Ratings

Latest Ratings

StockFirmActionPT
NIUDaiwa CapitalInitiates Coverage On41.5
QMCONorthland Capital MarketsInitiates Coverage On12.0
IBKRJefferiesInitiates Coverage On89.0
MRETFTD SecuritiesDowngrades18.5
SWKSGoldman SachsDowngrades135.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com